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Neuraxial injection of opioids provides effective analgesia in many types of surgery. To make patient pain-free, early ambulatory and for better neonatal care usually, intrathecal morphine is used for the lower segment cesarean section (LSCS). However, spinal opioids are associated with a wide variety of side effects such as nausea, vomiting, and pruritus.\[[@ref1]\] The incidence of postoperative nausea and vomiting (PONV) in patients with an intrathecal opiate is 60%--80%.\[[@ref2]\] The reported incidence of intrathecal opioid-induced pruritus is 20%--100%, more in postpartum cases.\[[@ref3]\] Although the prophylactic and therapeutic effects of several antiemetic and antipruritic drugs have been studied extensively, preventing PONV and pruritis after intrathecal opioids remains still a major challenge.

Risk factors of PONV are many including patient factors (age, female gender, and obesity); surgery-related factors (middle ear, abdominal, and laparoscopic surgery); anesthesia-related factors (use of volatiles, opioids, and N2O) and other factors such as prior history of motion sickness, nonsmoking state, anxiety, postoperative pain, and early oral intake. Above study included female patients of the almost equal age group who received neuraxial morphine for cesarean section. Hence, all patients\' characteristics and risk factors are similar in three groups.

5 hydroxytryptamine 3 (5HT3) receptor antagonist is widely used as the first line therapeutic agent for prevention of PONV and pruritus with good efficacy and minimal side effect.\[[@ref4]\] Palonosetron, a newer 5HT3 antagonist, has a unique mechanism different from older agents with more potency and persistent effects. In contrast to the older 5HT3 antagonist, palonosetron\'s allosteric binding and positive cooperation triggers receptor internalization, which results in persistent inhibition of 5HT3 receptor function and long duration of action.\[[@ref5]\] Studies have proved palonosetron to be a better antiemetic than ondansetron.

Dexamethasone is also one of the commonly used drugs for prevention of PONV. In 120 patients who received epidural morphine 3 mg for postcesarean delivery analgesia, dexamethasone 8 mg significantly decreased the incidence of PONV compared to placebo.\[[@ref6]\] The efficacy of dexamethasone as an antipruritic drug after intrathecal opioid has not been studied.

It is recommended that patients at high risk of developing PONV should receive a combination of two or more different classes of antiemetic agents rather than a single drug because none of the available antiemetic is entirely effective in preventing PONV.\[[@ref7]\]

It has been demonstrated that 5HT3 receptor antagonist (ondansetron, ramosetron) with dexamethasone is more effective in preventing PONV than ondansetron, ramosetron or dexamethasone alone.\[[@ref8][@ref9][@ref10][@ref11]\] All these studies included patients groups receiving intravenous (i.v.) patient-controlled analgesia (PCA) with opioids, but Szarvas *et al*. studied this drug combination in patients receiving intrathecal morphine and did not find any benefit of ondansetron and dexamethasone combination over ondansetron alone.\[[@ref12]\]

Recently, it was reported that combination of palonosetron and dexamethasone is more effective than palonosetron alone for prevention of PONV.\[[@ref13][@ref14]\] Studies by Bala *et al*. also prove the same, but all these studies were carried out on patients who underwent general anesthesia (GA).\[[@ref15]\] None of the studies included patient groups who have intrathecal morphine as a risk factor of PONV. Data related to the efficacy of above drug combination in LSCS patients receiving intrathecal morphine is lacking.

Hence, the purpose of the study was to assess whether combination therapy using palonosetron and dexamethasone is more effective in preventing PONV and pruritus than monotherapy with palonosetron or dexamethasone in women receiving intrathecal morphine for LSCS.
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After obtaining the Institutional Ethical Committee approval and written informed consent from each patient, we studied 90 adult female American Society of Anesthesiologists physical status class I who were to undergo LSCS during the period of 1 year (October 2016--August 2017). Patients with systemic diseases, mothers having compromised fetus, contraindication to regional anesthesia, pregnancy-related complication such as eclampsia and acute obstetric hemorrhage, smokers, need of GA due to the failure of regional anesthesia, history of motion sickness and pruritic skin disease, on steroid medication, hypersensitivity to study drugs were excluded from the study.

Patients were allocated using computer-generated random numbers to receive one of the 3 treatments regimes. Group *P* received palonosetron 0.075 mg, Group D received dexamethasone 8 mg and Group PD received palonosetron 0.075 mg and dexamethasone 4 mg single dose. Patients, anesthesiologists involved and investigators, who collected postoperative data, were unaware of group allocation. In operation theater, all patients were given a 18G i.v. cannula and Ringer\'s lactate 500 ml was given as preloading. All standard monitors such as pulse oximetry, noninvasive blood pressure, electrocardiography leads were attached. Under all aseptic measure, lumbar puncture was done in left lateral position with 25G spinal needle through a midline approach in L2--L3/L3--L4 interspace. Anesthesia was established with a single bolus dose of 0.5% hyperbaric bupivacaine 2.2 ml and 150 μg morphine. The study drug was given slowly i.v. immediately after SA. All study drugs were diluted to 5 ml with NS by O. T technician and anesthesiologist delivering anesthesia was unaware of the drug composition. Midazolam 1--2 mg i.v. given for intraoperative sedation after baby delivery. Supplemental oxygen at 4--6 L/min through a venturi mask was given.

Postoperatively, all patients were shifted to the recovery room. Injection diclofenac aq. 75 mg i.v. given as rescue analgesic. Nausea was defined as an unpleasant sensation associated with awareness of the urge to vomit. Vomiting was defined as the forceful expulsion of gastric contents from the mouth and pruritus was defined as the sensation that provokes the desire to scratch. Failure of PONV prophylaxis was defined as any episode of nausea or vomiting requiring rescue antiemetic. Failure of pruritic prophylaxis was defined as any episode of itching that provokes the desire to scratch or use of rescue antipruritic. Injection metoclopramide was given for rescue treatment of PONV and injection naloxone for pruritus, respectively. PONV and pruritus were assessed at 30 min, 2, 4, 8, 16, and 24 h after surgery by an investigator. The PONV scoring was 0 = no nausea or vomiting; 1 = nausea; 2 = retching; 3 = vomiting. Pruritus score was 0 = no pruritus; 1 = mild pruritus; and 2 = severe pruritus requiring treatment.
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Demographic variables were compared using Student\'s *t*-test. Chi-square test was done for noncategorical variables. Data are presented as the mean ± standard deviation, numbers or percentages. SPSS for windows version 20 (IBM) was used for statistical analysis.
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A total of 120 patients screened and 90 among them were randomized into three groups. The three groups were similar in terms of age, weight, the intrathecal opioid dose used, history of PONV, motion sickness and pruritic skin disease, and duration of operation \[[Table 1](#T1){ref-type="table"}\].
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Demographic data
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The proportion of PONV in the first 24 h postoperative period was 8 (26.6%) in the Group P, 12 (40%) in Group D and 6 (20%) in Group PD. On comparing the *P* value between Group *P* and palonosetron-dexamethasone, the difference was insignificant. Use of rescue antiemetic was more in Group D than Group *P* palonosetron-dexamethasone. The incidence of failure of PONV prophylaxis was more in three groups during the first 4 h. For first 16 h, nausea and vomiting was more in dexamethasone group than Group *P* and Group PD \[[Table 2](#T2){ref-type="table"}\]. However, after 16 h, there was no significant difference between three groups. The need of rescue antiemetic was more in Group D (30%) than Group *P* (6%) and Group PD (3%).

###### 

Proportion of patients who had nausea, vomiting, and need for rescue drug
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The incidence of pruritus for 24 h of surgery was 1 (3%), 2 (6%), and 1 (3%) in Group P, dexamethasone and palonosetron-dexamethasone, respectively \[[Table 3](#T3){ref-type="table"}\]. There was no statistically significant difference in need of rescue antipruritic drug between three groups \[[Table 4](#T4){ref-type="table"}\]. There is no statistically significant difference in the incidence of vomiting and rescue antiemetic drug requirement between group *P* and group PD(*P*\>0.05) \[[Table 4](#T4){ref-type="table"}\].
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Proportion of patients having pruritus and use of antipruritic drug
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*P* value between different groups
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The pathophysiology of PONV is complicated, and several kind of receptors and their mediators have been implicated in PONV. (1) Serotonin type 3 (5HT 3 receptor), (2) dopamine type 2 receptor, (3) histamine type 1 receptor, (4) muscarinic cholinergic type 1 receptor, (5) steroid receptor and (6) neurokinin type 1 (NK1) receptor. Based on these findings, modern PONV prophylaxis adopts the principle of a multimodal approach to treat high-risk patients with at least 2 or 3 different kind of receptor antagonists, rather than increasing dosage of one single receptor antagonist.\[[@ref16]\]

Historical data indicate 60%--80% of patients who receives no antiemetic prophylaxis after undergoing cesarean section proceeding with neuraxial opioids have PONV. Even though new antiemetic drugs have been introduced, there are no agents that can completely prevent or treat PONV due to multifactorial etiology and various receptor sites involved in PONV. Therefore, in patients at high risk for PONV, it is recommended that combination therapy using several antiemetics targeting different receptor sites be employed rather than using a single antiemetic agent.\[[@ref7]\]

Above study included female patients who received neuraxial morphine for cesarean section. All patients\' characteristics and risk factors were similar in three groups as concluded from [Table 1](#T1){ref-type="table"}. In this study, combination of palonosetron 0.075 mg and dexamethasone 8 mg was compared with either drug alone during the first 24 h after surgery. Several drug combinations have been studied. Selective 5HT3 antagonists have been extensively studied so far and are currently primary therapy for PONV prevention because they have fewer side effects, such as sedation or extrapyramidal symptoms as compared with other antiemetics. First generation 5HT3 antagonists such as ondansetron, dolasetron, tropisetron, granisetron, and ramosetron exert an effect through competitive binding at 5HT3 receptor site which antagonises the effect of serotonin centrally and peripherally.\[[@ref7]\]

Palonosetron is a second generation 5HT3 antagonist that has a high affinity for the 5HT3 receptor and longer plasma half-life (exceeding 40 h) than older antagonists (5--12 h) which results in prolonged inhibition of receptor function.\[[@ref17][@ref18]\] Following characteristics distinguishes palonosetron from first generation antagonists. The first palonosetron differs in chemical structure. It is a fused tricyclic ring system attached to a quinuclidine moiety unlike older drugs who are three substituted indole structure resembling serotonin. Second, palonosetron exhibits allosteric binding and positive cooperativity when binding to the 5HT3 receptor, triggering receptor internalization resulting in prolonged inhibition of receptor function.\[[@ref19]\] Third, palonosetron also inhibits responses induced by substance P, the dominant mediator of delayed emesis after chemotherapy through differential inhibition of 5HT3/NK1 receptor crosstalk.\[[@ref20]\]

These pharmacologic characteristics of palonosetron could decrease the need for combination therapy generally required for PONV prophylaxis in high-risk patients. Kovac *et al*. showed that palonosetron 0.075 mg effectively reduced PONV up to 72 h after an operation compared to placebo.\[[@ref21]\] It was a dose -- ranging study, and they found 0.075 mg dose of palonosetron was an effective dose. In addition, palonosetron 0.075 mg was more effective than ondansetron 4 mg and ramosetron 0.3 mg in the prevention of PONV during first 48 h after lap surgery in high-risk women receiving fentanyl-based i.v. PCA.\[[@ref22]\]

Dexamethasone has been postulated to be an effective antiemetic after pediatric and general surgery.\[[@ref23][@ref24]\] It has also been suggested that dexamethasone decreases the incidence of PONV after neuraxial opioid.\[[@ref25]\] In a study with 120 parturients who received epidural morphine (3 mg), dexamethasone 8 mg iv significantly decreased the incidence of PONV compared with placebo (18% and 51%, respectively).\[[@ref6]\] Although the exact mechanism for dexamethasone antiemetic effect is not well-known, it may exert central antiemetic action mainly through activation of glucocorticoid receptors in the nucleus of solitary tract, the nucleus of raphe and the area postrema. A meta-analysis to assess the efficacy of dexamethasone in reducing PONV showed that a single i.v. dose of dexamethasone 5--10 mg was effective in reducing PONV in women receiving neuraxial morphine for cesarean delivery or abdominal hysterectomy.\[[@ref26]\]

However, in the present study group receiving dexamethasone monotherapy had 40% incidence of PONV as compared to other two groups where the incidence was 26% in Group *P* and 20% in Group PD. This would suggest a lack of efficacy of dexamethasone in preventing PONV in postcesarean patients who had received neuraxial morphine. This difference between our study and above study concludes that PONV produced by higher doses of morphine as used epidurally can be more readily reversed by dexamethasone than can PONV after an intrathecal dose. Moreover, PONV usually occurs during first 6 h after intrathecal morphine but 6--24 h after epidural morphine; whereas dexamethasone has a biological half-life of 36--72 h proving its better control of chemorelated delayed emesis (beyond 24 h) as compared to classic antiemetics.\[[@ref27][@ref28][@ref29][@ref30]\] A study by Jadon *et al*. noted a lag period of 4 h before dexamethasone effect could be observed.\[[@ref31]\] Hence, it is unable to provide prophylaxis against PONV in the immediate postoperative period. Hence, delayed antiemetic efficacy might be the result of its pharmacokinetics, which may partially explain the lack of antiemetic effect during the 24 h observation period adopted for this study.

A number of studies have reported that combination therapy using 5HT3 receptor antagonists, such as ondansetron, tropisetron, or ramosetron with dexamethasone were more effective in reducing PONV than monotherapy.\[[@ref32][@ref33]\] Palonosetron being a newer 5HT3 receptor antagonist, with better efficacy than ondansetron; its combination with dexamethasone was also used. However, Blitz *et al*. claimed that palonosetron with dexamethasone did not reduce the incidence of PONV compared to palonosetron alone.\[[@ref12]\] His study included elective outpatient laparoscopic abdominal or gynecological surgery with subjects having at least 3 Apfel\'srisk factors for PONV, who were followed up for 72 h postoperatively (postoperative 0--2 h, 19 vs. 16%, 0--6 h 44 vs. 42%, 6--72 h; and 42 vs. 28%, palonosetron vs palonosetron + dexamethasone, respectively).\[[@ref34]\] Bala *et al*. studied patients with high risk of PONV with added volatile and N2O. Their study was contrary to Blitz where N2O and volatiles were not used.\[[@ref15]\] Bala concluded that Nausea occurred in 42.9% and vomiting in 33.3% in palonosetron group, whereas Nausea 14.3% and vomiting in 11.9% in *P* and D group during first 24 h postoperatively. Rajeeva *et al*. said that although the combination of dexamethasone and the older 5HT3 antagonist is more effective than 5HT3 antagonist alone, same is not true for the combination of dexamethasone and palonosetron.\[[@ref35]\]

There has been no study evaluating palonosetron (0.075 mg) and dexamethasone (4 mg) combination to palonosetron or dexamethasone alone for intrathecal opioid-induced PONV. In our study *P* and D (0.075 mg palonosetron and 4 mg dexamethasone) combination was found to be equally effective as palonosetron (0.075 mg) alone but better than dexamethasone (8 mg) alone for PONV in cesarean section patient receiving intrathecal morphine. All patients had high-risk factors as all were female, nonsmoker status, receiving intraoperatively morphine. Rescue antiemetic requirement was more in Group D during early hours than the other two groups. There was no statistically significant difference between Group *P* and Group PD regarding rescue antiemetic consumption showing that combining dexamethasone and palonosetron does not give any additional benefit to patients.

Szarvas *et al*. conclude that ondansetron and dexamethasone combination was no better than ondansetron alone in patients undergoing a major orthopedic operation with spinal morphine as an adjuvant. The difference in studies between Rajeeva and Szilvia might be due to different patient groups in both studies. In Szilvias study, intrathecal morphine was used, whereas Rajeeva\'s patients were given GA. Hence, different patient groups, undergoing different surgeries with different anesthetic techniques need unique anti-emetic combination therapies for better PONV prophylaxis. The study tried to establish the efficacy of the combination of the newer 5HT3 antagonist, i.e., palonosetron with dexamethasone in pregnant patients receiving intrathecal morphine for LSCS.

Pruritus is an unpleasant and irritating sensation leading to scratching of the skin. It is the very common adverse effect of neuraxial opioids with the highest prevalence, i.e., up to 100% associated with intrathecal morphine administration which being water soluble. Parturients are more susceptible to pruritus with an incidence between 60% and 100%, and it appears to be estrogen related and dose-dependent.\[[@ref36]\]

In the present study, low dose morphine (\<200 μg) was used which resulted in a lesser incidence of pruritus complaints, but since there was no control group in our study, this could not be absolutely concluded.

Bonnet *et al*. reviewed the effect of prophylactic 5HT3 receptor antagonist on pruritus induced by neuraxial opioids concluding that they are helpful in decreasing the severity as well as incidence of pruritus.\[[@ref37]\] Later, George *et al*. also concluded that 5HT3 receptor antagonist when used as prophylaxis decreased the severity of pruritus in women undergoing C-section with intrathecal morphine.\[[@ref38]\] Jadon *et al*. did their study on such of patients with dexamethasone prophylaxis. They, however, concluded that dexamethasone alone did not reduce the incidence of pruritus.

The study results were much similar to above studies as there was a significant difference between the group receiving dexamethasone alone and the other two groups, regarding incidence of pruritus as indicated in [Table 4](#T4){ref-type="table"}. This clearly indicates that only dexamethasone as prophylaxis does not control intrathecal morphine-induced pruritus. However, palonosetron whether alone or in combination with dexamethasone was able to control pruritus.
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Palonosetron and palonosetron--dexamethasone combination is superior to dexamethasone group alone in preventing intrathecal morphine-induced postoperative vomiting and pruritus. A combination of palonosetron and dexamethasone does not decrease the incidence of PONV and pruritus more compared to the only palonosetron. Hence, we recommend not to add dexamethasone to palonosetron as it will further increase the cost, risk of added side effects without any extra benefit.
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